Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents

Ingar Seemann · Johannes A. M. te Poele · Ji-Ying Song · Saske Hoving · Nicola S. Russell · Fiona A. Stewart

Received: 19 July 2013/Accepted: 18 September 2013/Published online: 4 October 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract In Her2-positive breast cancer patients, inhibition of epidermal growth factor receptor 2 (ErbB2)-signaling is often combined with chemotherapy and radiotherapy. The risk of cardiac toxicity after anthracyclines and radiotherapy is recognized, but little is known about increased risk when these treatments are combined with ErbB2 inhibition. This study investigated whether ErbB2 inhibition increased radiation or anthracycline-induced toxicity. In an in vitro study, human cardiomyocytes were treated with irradiation or doxorubicin, alone or in combination with trastuzumab, and evaluated for cell survival and growth. Groups of mice received 0 or 14 Gy to the heart, alone or in combination with lapatinib, or 3 × 4 mg/kg doxorubicin alone or in combination with lapatinib. Mice were evaluated 40 weeks after treatment for cardiac damage. Changes in cardiac function (99mTc-Myoview gated SPECT) were related to histomorphology and microvascular damage. Radiation or doxorubicin-induced cardiomyocyte toxicity (in vitro) were not exacerbated by trastuzumab. Cardiac irradiation of mice decreased microvascular density (MVD) and increased endothelial damage in surviving capillaries (decrease alkaline phosphatase expression and increased von Willebrand factor), but these changes were not exacerbated by lapatinib. Inflammatory responses in the irradiated epicardium (CD45+ and F4/80+ cells) were significantly reduced in combination with lapatinib. Irradiation, doxorubicin, and lapatinib each induced cardiac fibrosis but this was not further enhanced when treatments were combined. At the ultra-structural level, both lapatinib and doxorubicin induced mitochondrial damage, which was enhanced in combined treatments. Lapatinib alone also induced mild changes in cardiac function but this was not enhanced in the combined treatments. Trastuzumab did not enhance direct radiation or anthracycline toxicity of cardiomyocytes in vitro. Lapatinib did not enhance the risk of radiation or anthracycline-induced cardiac toxicity in mice up to 40 weeks after treatment, but mitochondrial damage was more severe after doxorubicin combined with lapatinib.

Keywords ErbB2 · Cardiac microvasculature · Irradiation · Anthracyclines

Introduction

Cardiovascular damage has been reported as a long-term toxicity in breast cancer survivors previously treated with radiotherapy (RT) and anthracycline chemotherapy (CT) [1]. Prospective functional imaging studies show that ~40 % of left-sided breast cancer patients treated with RT develop asymptomatic cardiac perfusion defects within 2 years and about 16 % eventually develop wall-motion abnormalities [2–4]. Yearly, 1.5 million new breast cancer
patients are diagnosed worldwide who will undergo RT, CT, surgery, and/or adjuvant hormonal therapy. Approximately 15–20 % of breast cancers show a highly aggressive subtype, characterized by epidermal growth factor receptor 2 (ErbB2) overexpression. Such cancers are fast-growing, highly invasive, resistant to CT and RT and are therefore associated with higher risk for recurrence [5, 6]. Epidermal growth factor receptor 1 (ErbB1) is also expressed in several human tumors, including breast cancer, and makes significant contributions to invasion and growth of tumors [7].

The established role of ErbB1 and ErbB2 in breast cancer makes them attractive therapeutic targets. Trastuzumab, a humanized anti-ErbB2 monoclonal antibody, is the most prominent, first-line agent for ErbB2 (HER2)-overexpressing metastatic breast cancer [8]. Clinical studies using trastuzumab confirmed the benefits of inhibiting ErbB2 signaling, including inhibition of p27Kip1, activation of PTEN tumor suppressor gene and induction of G1 cell cycle arrest [9]. Adjuvant treatment with trastuzumab for operable breast cancer improves overall survival rate in Her2-positive breast cancer patients by ~30 % and reduces the risk of recurrence by ~50 % [10, 11]. However, heart failure occurs in 1.7–4.1 % of patients treated with trastuzumab and cardiac toxicity lead to discontinuation of the adjuvant treatment in 19 % of the patients [10–12].

ErbB2 is an orphan receptor that has no ligand binding site but dimerizes with other ligand-bound EGRF receptors (HER3, HER4). One of the most common ligands of the EGFR pathway in the heart is neuregulin-1. Targeting both ErbB1 and ErbB2 is hypothesized to have superior therapeutic effects relative to single-agent treatment. Dual inhibitor lapatinib (GW572016) is a small molecule, reversible inhibitor of the tyrosine kinase activities of ErbB1 and ErbB2 at equal potency. Lapatinib works by blocking the signaling transduction to Ras/Raf MAPKs and the PI3K/Akt pathway, which leads to increased apoptosis and decreased cellular proliferation. Perez and colleagues reviewed 44 studies in which lapatinib (as monotherapy or in combination with previously given anthracyclines or trastuzumab) induced low levels of cardiac toxicity, as detected by reversible decreased left ventricle ejection fraction (LVEF) [13].

The mechanisms whereby cardiac toxicity occurs after ErbB2 inhibition is not fully understood, since non-malignant cells do not over-express ErbB2. However, ErbB2 signaling and the ligand Neuregulin-1 are known to play a crucial role in survival and growth of cardiac myocytes [14, 15]. Moreover, a recent study demonstrated that irradiation inhibited ErbB2 signaling in rat hearts until the onset of fibrosis after 10 weeks. As fibrosis progressed, ErbB2 and the EGFR ligand neuregulin were significantly upregulated, presumably as an attempt to regenerate the myocardium [16]. This raises the question whether delayed inhibition of ErbB2 after CT or RT could lead to increased cardiac toxicity.

Little is known about the long-term cardiac outcome of lapatinib in combination with anthracycline CT or irradiation. In this study, we first investigated whether blocking of ErbB2 enhanced the toxicity of radiation- or doxorubicin (Dox)-treated cardiomyocytes in vitro. We subsequently investigated the influence of combined ErbB1/2 inhibition in mice treated with cardiac irradiation or systemic Dox. For these studies lapatinib was given for 20 weeks in the chow, either at the time of irradiation or Dox (direct), or delayed until 20 weeks after irradiation or Dox. This was designed to mimic clinical treatment protocols and to investigate the influence of lapatinib on the short- and long-term damage repair process following irradiation or anthracyclines. Structural and functional changes were monitored at 40 weeks after treatment to determine whether ErbB1/2 inhibition caused increased cardiac damage or inhibited recovery after radiation or anthracycline treatment.

As far as we are aware, this is the first study that characterizes in detail long-term cardiac toxicity after lapatinib in combination with irradiation or Dox.

Methods

Cell culture conditions and treatment

Human cardiac myocytes (HCM) from Promocell (Heidelberg, Germany) were cultured in DMEM (Gibco®, Invitrogen) supplemented with 10 % fetal calf serum, 1 % penicillin, and 1 % streptomycin at 37 °C with 5 % CO2. The HCM express markers of early stage differentiation such as GATA-4 and sarcomeric alpha-actin and act more like progenitor cells with capacity for proliferation. For irradiation experiments, cells were seeded in 96-well plates (1,000 per well) and irradiated with 0, 2.5, 5, or 10 Gy (137Cs irradiation, with a dose rate of 0.66 Gy/min) before exposure to 0, 0.1, 1, or 10 μg/ml trastuzumab (Roche, from the Netherlands Cancer Institute pharmacy) for 14 or 21 days. Cells were then washed (3 × with PBS) to remove drugs and evaluated for cell viability. For Dox experiments, 4,000 cells per well were seeded and treated with 0, 0.0025, 0.025, 0.25, 2.5, 25, and 250 μg/ml Dox (Doxorubicin hydrochloride 2 mg/ml PCH, from the Netherlands Cancer Institute pharmacy) and trastuzumab (0–10 μg/ml) for 3 days, washed and evaluated for cell viability directly or re-incubated with trastuzumab until evaluation at 14 days. Cell viability was detected by cell counting kit-8 (CCK-8, Sigma, Zwijndrecht, the Netherlands) following the manufacturer’s protocol.
Mice and treatments groups

Male C57BL/6 mice, aged 8–12 weeks (Charles River Laboratories, France) were randomly allocated to receive 0 Gy or 14 Gy to the heart, or 4 mg/kg Dox intraperitoneal (i.p.) weekly for 3 weeks. Separate cohorts of animals were included for irradiation or anthracycline combined with lapatinib, as well as age matched controls. Lapatinib (from the Netherlands Cancer Institute pharmacy) was mixed with standard mouse chow to a final concentration of 0.48 g/kg. Assuming consumption of 5 g chow/mouse/day, this is equivalent to 100 mg/kg/day. A pilot study with 100 mg/kg/day given in chow or by oral gavages resulted in the same plasma concentration (mean 946 ng/ml and 909 ng/ml lapatinib after chow diet and oral gavages). Lapatinib diet was either started 7 days before irradiation or Dox (direct schedule) to achieve steady state plasma levels, or delayed until 20 weeks after treatment (Fig. 1). Irradiation was with 250 kV X-rays, operating at 12 mA and filtered with 0.6-mm Copper. The dose rate was 0.94 Gy/min, with a field size of 10.6 x 15 mm (including the whole heart and up to 30 % lung volume); the rest of the mouse was shielded with lead. For irradiation, unanesthetized mice were immobilized in a prone position in acrylic perspex jigs. Each treatment group comprised 10–15 mice (n = 125 in total). Experiments were in agreement with the Dutch law on animal experiments and welfare, and in line with the international Guide for the Care and Use of Laboratory Animals (Eighth edition).

Tissue preparation for histology

At termination of the experiment, the heart was perfused via the aortic arch (retro-grade), under lethal sodium pentobarbital anesthesia (18 mg per mouse, i.p.), with PBS (frozen sections) or PBS followed by 1 % paraformaldehyde (paraffin sections). The heart was then quickly excised before freezing on dry ice or immersion in 1 % paraformaldehyde.

Cross-sections were cut at the level of the mid-horizontal plane from fixed paraffin-embedded tissues (4 μm) or frozen tissues (7 μm).

Frozen sections

An anti-CD31 antibody (1:50, Becton&Dickinson) was used to visualize cardiac vasculature. To determine functional changes in the microvasculature, a histochemical staining with Naphtol AS-MX/DMF and fast Blue BB salt was performed to detect endothelial cell alkaline phosphatase. Sections were also reacted with antibodies against von Willebrand Factor (vWF) (1:4000, Abcam, Cambridge, USA) as a marker of thrombotic changes. All sections were processed identically, with precisely the same incubation times for the primary and secondary antibody and diaminobenzidine (DAB) solution (Sigma, Zwijndrecht, the Netherlands).

For quantification of microvascular changes, five random fields (40 x objective) of the heart were photographed with a CCD 2 Color Microscope system, including a Zeiss AxioCam color camera (Axiocam HRc, Zeiss, Göttingen, Germany). A computerized morphometry system (Leica Qwin V3, Leica, Rijswijk, the Netherlands) was used to quantify the MVD of CD31 positive structures. Vessels <1.5 or >200 μm² were automatically excluded from the measurements. Photographs of whole sections stained for ALP and vWF were taken with an Aperio scanner (Scanscope-XT, Aperio technologies, Vista, USA) using 40 x objective. Analyses of the percentage myocardium, excluding endocardium, positive for each marker were done with a computerized morphometry system (Leica Qwin V3).
**Paraffin sections**

To determine the extent of inflammation, sections were immuno-labeled with anti-CD45 antibody (1:400, Becton & Dickinson, Franklin lakes, USA). To detect alterations in the number of macrophages sections were stained with anti-F4/80 (1:300, AbD Serotec, Dusseldorf, Germany) and counted per left ventricle (LV) myocardial area.

All sections were processed identically; therefore, differences between the treatments are due to DAB identification of the relevant protein. Interstitial collagen was determined in the myocardium based on Sirius red staining. Photographs of the LV wall, excluding the septum, were taken using a 40× objective (Leica DFC320). Interstitial collagen was quantified in five randomly selected areas of the subendocardium and myocardium of the LV (40× objective) and results were expressed as percentage tissue positive for Sirius red relative to myocardial area. The number of CD45+ cells per section was counted separately in the epicard and myocard to determine the extent of inflammation. Morphometric parameters were analyzed using a computerized morphometry system (Leica Qwin V3). Transverse sections were stained with hematoxylin and eosin (H&E) to check for alterations in the myocardium and blood vessels. A semi-quantitative scoring system was used, whereby for the blood vessels 1 indicates one mild/severe morphological event (degeneration of the coronary arterioles, dilation of capillaries in myocardium accompanied by edema in stroma or clotting-like materials in coronary vessels), 2 indicates two morphological events, and 3 indicates >2 severe morphological events. For the myocardium, a score of 1 indicated atrophy, 2 indicated degeneration or hypertrophy, and 3 indicated more than two events.

**Electron microscopy (EM)**

Tissues were fixed in Karnovsky’s fixative, followed by 1 % osmiumtetroxide in 0.1 M cacodylate-buffer. After washing, pellets were stained with Ultrastain 1 (Leica, Vienna, Austria), followed by ethanol dehydration. Finally the cells were embedded in a mixture of DDSA/NMA/Embed-812 (EMS, Hatfield, U.S.A), sectioned and stained with Ultrastain 2 (Leica, Vienna, Austria) and analyzed with a CM10 electron microscope (FEI, Eindhoven, the Netherlands).

**Gated SPECT/CT**

Gated single photon emission computed tomography (gSPECT) acquisitions were made with a small-animal NanoSPECT/CT (Bioscan Europe, Ltd., Paris, France). Animals were anesthetized with Hypnorm (Fentanyl 0.26 mg/kg/Fluanisone 8.33 mg/kg, VetaPharma, Ltd., Leeds, UK) and Dormicum (Midazolam, 4.17 mg/kg, Roche, Woerden, the Netherlands) via i.p. injection (1:2:1 Hypnorm:H2O:Dormicum; 120 μl/mouse). Myoview (GE-healthcare, Hoevelaken, the Netherlands) was labeled with 1–1.5 ml 99mTc-pertechnetate. For detailed information see Seemann et al. [17]. Quantitative analysis of the reconstructed datasets was performed on a clinical e.soft (syngo-based) workstation (Siemens Medical Solutions, Siemens AG, Erlangen, Germany), using algorithms to automatically reconstruct a count based 3D model of the dimensions of the left ventricular (LV) end-diastolic and systolic volumes (EDV, ESV). Subsequently, a LV time volume curve and its first derivative were generated. The ejection fraction (EF) was calculated based on the difference between EDV and ESV divided by EDV and peak filling rate (PFR) (EDV/s) was calculated from the Fourier-fitted curves.

**Statistics**

Data are expressed as mean ± SEM and groups were compared using non-parametric Mann–Whitney exact U-tests. Group differences were considered statistically significant at \( p < 0.05 \). Statistical analyses were performed using SPSS version 20.

**Results**

HER2 inhibition did not decrease myocyte cell viability in vitro

Exposure of human cardiomyocytes for 3 days to Dox induced a dose-dependent decrease in cell viability. However, combination of Dox with trastuzumab did not further decrease myocyte cell viability (Fig. 2a). When Dox was removed after 3 days and cells were evaluated at 14 days after treatment, cell proliferation was not affected by the presence of trastuzumab. Prior exposure to >0.025 μg/ml Dox inhibited cardiomyocyte growth, but this was independent of trastuzumab exposure (Fig. 2b).

Cardiomyocyte cell viability decreased after radiation doses of 2.5–10 Gy, when assessed at 14 or 21 days after treatment, but there was no further decrease in cell viability in combination with trastuzumab (Fig. 2c, d).

**Mouse survival and weight**

Irradiation with 14 Gy alone caused no premature deaths and few deaths occurred in combination with direct (7 %) or delayed lapatinib (12 %). Heart and body weights were slightly lower after irradiation (Fig. 3a and Table S1). There were more unscheduled deaths after treatment with Dox.
Fig. 2 Cardiomyocyte viability after ErbB2 inhibition. Fig a/b: Human cardiomyocytes were treated with doxorubicin (0–250 μg/ml) and trastuzumab (0–10 μg/ml) for 3 days. Cells were then washed (3× with PBS) to remove drugs and evaluated for cell viability directly (2a) or re-incubated with trastuzumab only until evaluation at 14 days (2b). Each symbol represents the mean (±SEM) of three experiments and results are expressed as percentage cell survival. Fig c/d: Human cardiomyocytes were irradiated (0, 2.5, 5, or 10 Gy) and then exposed to trastuzumab (0–10 μg/ml) for 14 days (c) or 21 days (d) before evaluation of cell viability. Each symbol represents the mean (±SEM) of three experiments and results are expressed as percentage cell survival.

Fig. 3 Kaplan-Meier estimated of overall survival shown for mice treated with lapatinib alone or in combination with radiation or doxorubicin. Survival data are shown for mice treated with radiation (a) or doxorubicin (b) alone or in combination with direct or delayed with lapatinib. Treatment groups were compared with age-matched controls. *indicates significant differences between treated mice and age matched control groups ($p < 0.05$; Mann–Whitney U-test).
(27 %), especially when combined with lapatinib (36 and 33 % deaths for direct and delayed lapatinib) (Fig. 3b; Table S2). Since the group analyses were done on material from surviving animals only, this probably represents an underestimate of the total toxic effects of Dox. Both heart and body weights were also lower after Dox alone or in combination with lapatinib compared to age-matched control.

Radiation-induced microvascular damage

MVD decreased significantly after 14 Gy radiation alone but the decline was not further enhanced by combination with either direct or delayed lapatinib treatment (Fig. 4a). There were no changes in MVD after Dox treatment alone or in combination with lapatinib (data not shown). Radiation-induced changes in MVD were accompanied by endothelial damage, as shown by a marked decrease in ALP activity (Fig. 4b) and an increased expression of the thrombotic endothelial marker vWF after irradiation alone (Fig. 4c). None of these endothelial changes were more severe after combined treatments with lapatinib then after irradiation alone (Fig. 4b, c). Endothelial damage (ALP) or thrombotic changes in the microvascular (vWF) were not detected in Dox-treated mice (data not shown).

Radiation-induced inflammation

Irradiation alone led to a significant increase in CD45+ cells and F4/80+ cells in the epicardium (Fig. 5) but not in the myocardium (data not shown). Strikingly, direct or delayed lapatinib decreased CD45+ and F4/80+ cells in the irradiated epicardium, compared to irradiation alone (Fig. 5a, b). There were no significant inflammatory responses seen in Dox-treated mice (data not shown).

Irradiation- and doxorubicin-induced cardiac fibrosis

Cardiac fibrosis was significantly increased by irradiation or lapatinib alone, when administrated directly (Fig. 6a). Lapatinib (either direct or delayed) did not further enhance the fibrosis induced by irradiation. There was also a significant increase in cardiac fibrosis after Dox alone, but this was not further enhanced by either direct or delayed lapatinib (Fig. 6b).

Structural and morphological alterations

H&E stained sections were semi-quantitatively analyzed for changes in the myocardium and blood vessels. There were only minor changes in the vasculature after irradiation alone.
or in combination with direct lapatinib. However, when delayed lapatinib was given to irradiated mice there was a trend for increased myocardial and blood vessel damage, including dilation of capillaries, degeneration of coronary arteries, degeneration of the myocardium, and hypertrophy of the myocardium (Fig. 7). No severe changes were detected in Dox-treated mice that survived until 40 weeks. Examination of prematurely sacrificed, sick animals did demonstrate damage but this group comprised only a few mice, sacrificed at various times after treatment, so no semi-quantitative analysis was done. Electron microscopy (EM) analysis indicated small changes in myocyte morphology, like local vacuolization, after Dox or lapatinib treatment alone. Changes were enhanced when Dox was combined with lapatinib, either direct or delayed. Focal damage was seen with degenerative changes in the mitochondria, cloudy-swollen phenotype and disorganized, disrupted Z-bands in some cardiomyocytes, but normal looking mitochondria and Z-bands in adjacent cells (Fig. 8).

Lapatinib decreased left ventricle function

Cardiac function tests, determined by gated SPECT/CT, showed increases in ESV after lapatinib alone (34 and 16 % increase for direct and delayed schedules) (Fig. 9). Similar increases in EDV were seen (11 and 9 % for direct and delayed schedules) (data not shown). This resulted in decreased EF (22 and 9 % decreases after direct and delayed lapatinib) (Fig. 9). PFR, maximum down slope of left-ventricular volume, also showed significant decrease after lapatinib treatment (20 and 21 % after direct and delayed lapatinib) (Fig. 9). Neither 14 Gy nor 3 × 4 mg/kg Dox induced significant changes in cardiac function, either given alone or in combination with lapatinib.

Discussion

In this study, we investigated the effect of direct and delayed inhibition of EGFR signaling combined with irradiation or Dox on cardiomyocyte survival, morphological damage, and heart function. We demonstrated that inhibiting ErbB2 in combination with irradiation or anthracyclines did not further decrease myocyte cell viability in vitro. Combined inhibition of ErbB1 and ErbB2 also did not enhance radiation or Dox induced cardiac damage in mice. Indeed, the radiation-induced inflammatory responses were inhibited by lapatinib.
Inhibition of ErbB2 in HER2-overexpressing breast cancers became a standard (adjuvant) treatment as it results in improvement of outcome [18]. Often this is combined with anthracycline CT [19]. In addition, most patients receive adjuvant RT, either after breast conserving surgery or mastectomy [20]. Previous studies have shown an increase in cardiac events after combining RT with anthracyclines, such as decline in LVEF or congestive heart failure [11, 13, 21]. Long term follow up studies with ErbB2 inhibiting agents combined with these modalities are ongoing to determine both efficacy and safety, especially with regard to cardiac toxicity (ALTTO study; BIG 2-06/N063D).

EGFR signaling, including ligand NRG-1, plays an important role in adult cardiomyocyte survival, since it activates the pro-survival PI3K/pathway and stimulates cardiomyocyte maintenance and function [22]. Previous studies in our lab, demonstrated the ability of the mouse heart to compensate functionally for significant structural damage after previous irradiation [17]. Compensatory mechanisms and pro-survival pathways might play a role in maintaining cardiomyocyte function in a damaged heart, at least until the extent of damage overwhelms the potential for stimulated survival. Sridharan et al. [16] recently demonstrated upregulation of ErbB signaling in the irradiated rat heart in parallel with developing cardiac fibrosis, leading to the suggestion that ErbB signaling and pro-survival pathways are activated in an attempt to regenerate the myocardium. Moreover, inactivation of ErbB4 in ventricular muscle cells led to a severe dilated cardiomyopathy, demonstrating the important role of ErbB signaling in the myocardium [23].

This raises the question of whether inhibition of these pathways could impair attempts of the damaged heart to
we found increased expression of both ErbB2 and ErbB4 in mouse hearts at 40 weeks after irradiation, in parallel with developing fibrosis (Supplementary Fig. 1). However, this upregulation was not inhibited in the presence of lapatinib. Our data also do not indicate cardiac dysfunction after radiation alone or in combination with lapatinib, in contrast to the mild but significant changes in cardiac function after lapatinib alone (Fig. 9). These data are consistent with the important role of ErbB signaling to maintain myocardium functionality and imply that this compensatory mechanisms initiated by irradiation still operate in the presence of lapatinib.

Treatment of adult human cardiomyocytes, which have low expression of HER2, with trastuzumab, did not alter cell viability, nor did it enhance toxicity induced by either radiation or Dox (Fig. 2). This is consistent with the knowledge that anthracyclines cause acute irreversible damage to the cardiomyocytes through generation of free radicals and cardiomyocyte apoptosis [24], whereas trastuzumab-induced cardiac toxicity is dose-dependent and largely reversible [25]. The doses of trastuzumab we used were sufficient to cause significant reduction in viability in HER2-overexpressing tumor cells (data not shown), but the cardiomyocytes were less sensitive to ErbB2 inhibition. Some studies, using HER2-overexpressing breast cancer cells, have shown that inhibition of PI3K-pathway may be bypassed by lateral activation of other members of the HER family (Her3) [26, 27]. This raises the possibility, that activation of this compensatory feedback loop could thereby stimulate survival of cardiomyocytes.

Our in vitro results contrast somewhat with a recently published study by Hasinoff et al., in which pretreatment of isolated neonatal rat cardiac myocytes with HER1/HER2 inhibitor lapatinib potentiated doxorubicin-induced myocyte damage, assessed by LDH release and disrupted sarcomeres, although there was no enhancement of doxorubicin-induced apoptosis. A major difference between our study and that of Hasinoff is that they used neonatal cardiomyocytes and neuregulin is essential for the developing heart, which probably increases cardiomyocyte sensitivity to ErbB2 inhibition. In our study, we investigated the effects of trastuzumab (ErbB2 inhibitor) on adult cardiomyocyte survival after Dox or irradiation. We did not look at changes in cardiomyocyte function or morphology in vitro. However, our EM study from in vivo experiments would suggest enhanced cardiomyocyte damage from the combination of lapatinib and Dox, consistent with the data of Hasinoff.

Our findings suggest that trastuzumab or lapatinib induced cardiac toxicity acts by different mechanisms than anthracyclines or radiation. This raises the possibility that the cardiac toxicity seen in clinical studies where ErbB2 inhibition is combined with anthracyclines could be due to indirect effects, for example endothelial cell dysfunction and loss, with secondary damage to the cardiomyocytes.

We have previously shown [17] that local cardiac irradiation induces microvascular loss and damage. The current study shows that irradiation-induced endothelial damage per cardiomyocyte. Mitochondrial volume increased, mitochondrial cristae were fuzzy and had a cloudy swollen phenotype (arrow). d Direct lapatinib set up combined with doxorubicin (n = 3); e delayed lapatinib set up combined with doxorubicin (n = 3); disorganized mitochondria, mitochondrial cristae were fuzzy and had a cloudy swollen phenotype (arrow), increased volume of mitochondria. MI mitochondria; MF myofibril; Z z-bands; Dic Discus interculatis
dysfunction and loss was not further enhanced by lapatinib, either when given at the time of irradiation (direct) or delayed for 20 weeks. Mechanisms of radiation-induced cardiac toxicity include activation of TGFβ and production of chemokines and pro-inflammatory cytokines, which are largely independent of the PI3K-pathway determining cardiomyocyte survival. However, the MAPK pathway has been implicated in regulation of permeability in endothelial cells [28], something we found to be increased by irradiation. These observations are consistent with the concept that mechanisms of radiation-induced cardiac damage do not involve ErbB signaling.

Slow turnover tissues, like the myocardium, have a low proliferative capacity and a small stem-cell component, and therefore have a limited ability to repair damage. Radiation-induced cardiac toxicity is initiated by an acute inflammatory response, which progresses to fibrosis without proper tissue regeneration [29]. We found that the inflammatory response initially activated by irradiation was decreased by lapatinib. We can speculate that, since the MAPK pathway mediates myocardial pro-inflammatory cytokine production, inhibiting MAPK pathway with lapatinib may decrease the pro-inflammatory cytokine production [30, 31]. However, we have no data to support this hypothesis.

A further consequence of irradiation is the development of fibrosis. Similar to previous studies, our study showed increased cardiac fibrosis after irradiation or Dox alone. However, this was not further enhanced by lapatinib. On the other hand, 20 weeks of lapatinib alone in the direct set up induced fibrosis in mice sacrificed at 40 weeks. This is in contrast to no increase in fibrosis when lapatinib was delayed until 20 weeks and continued until sacrifice at 40 weeks. This might be explained by the delayed fibrotic response of the myocardium, which required time to develop after cessation of the lapatinib. We did not evaluate mice at later follow-up times than 40 weeks.

Changes in the microvasculature after Dox alone or with lapatinib were not seen. Nevertheless, fibrosis and degenerated cardiomyocytes (EM study) and 27–36 % animal lethality, as well as decreased cell viability in vitro, do indicate doxorubicin-induced damage to the myocardium via cardiomyocytes. Although anthracyclines induce acute damage, clinical symptoms are mostly detectable months or years after treatment [32]. Therefore, besides acute myocardial damage, late and indirect microvascular damage may occur at later times.

We conclude that ErbB2 inhibition did not enhance direct radiation or anthracyclines toxicity of cardiomyocytes in vitro. Radiation-induced microvascular damage was not further enhanced by ErbB2 inhibition and the inflammatory response was decreased. Myocardial damage was induced by anthracyclines but not further enhanced by ErbB2 inhibition. Treatment of mice with the ErbB 1/2-blocking agent lapatinib did not further enhance the risk of radiation or anthracycline-induced cardiac toxicity up to 40 weeks after treatment.

Acknowledgments The authors would like to thank Bert Pool, Department of Nuclear Medicine, The Netherlands Cancer Institute, for help with the NanoSPECT/CT and Dr. Jack Cleutjens, Department of Pathology, University of Maastricht, for help with the Leica Qwin morphometry system. Our thanks go to Hans Janssen and Nico Ong, Division of Cell Biology, The Netherlands Cancer Institute, for their expertise in electron microscopy. Moreover, we would like to thank Antsje Nolles and Sjoers van der Horst for their technical assistance regarding in vitro experiments and real-time PCR analysis.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
References

1. Bovelli D, Plataniotis G, Roila F (2010) Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v277–v282

2. Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH et al (2005) The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63:214–223

3. Prosnitz RG, Hubbs JL, Evans ES, Zhou SM, Yu X et al (2007) Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data to 6 years after treatment. Cancer 110:1840–1850

4. Lind PA, Paganelli R, Marks LB, Borges-Neto S, Hu C et al (2003) Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat Oncol Biol Phys 55:914–920

5. Nahta R, Hortobagyi GN, Esteva FJ (2003) Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8:5–17

6. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC et al (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599–605

7. Xue C, Wyckoff J, Liang F, Sidani M, Violini S et al (2006) Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced invasavation and metastasis. Cancer Res 66:192–197

8. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

9. Tan M, Yu D (2007) Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 608:119–129

10. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820

11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

12. Feldman AM, Lorell BH, Reis SE (2000) Trastuzumab in the treatment of metastatic breast cancer: antiangiogenesis therapy versus cardiotoxicity. Circulation 102:272–274

13. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E et al (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83:679–686

14. De Keulenaer GW, Doggen K, Lemmens K (2007) Role of anthracyclines in breast cancer: NSABP B-31. J Clin Oncol 25:2638–2644

15. Sridharan V, Sharma SK, Moros EG, Corry PM, Tripathi P et al (2013) Effects of radiation on the epidermal growth factor receptor pathway in the heart. Int J Radiat Biol 89(7):539–547

16. Swain SM (2008) Cardiovascular complications of breast cancer therapy. Clin Adv Hematol Oncol 6:247–248:282